LL-37: the antimicrobial peptide your body makes itself
LL-37 is a name that almost always comes up when people discuss antimicrobial peptides, because this molecule really is produced by the body itself. LL-37 is the only cathelicidin found in humans. Its name refers to 37 amino acids, beginning with two leucines. The molecule is cut from the precursor hCAP-18, a product of the CAMP gene, and its positively charged and amphipathic nature is related to how it interacts with microbial membranes.
Antimicrobial peptides, part of the body's natural defenses
LL-37 is often discussed in research on the body's first layers of defense, such as the skin and the airways. It is studied as part of the natural defense system, not as a replacement for antibiotics. Another peptide in the same catalog group is Thymosin Alpha-1, which is covered in Thymosin Alpha-1 and the immune system.
Why vitamin D is always mentioned alongside it
The vitamin D receptor is an important transcription factor for raising expression of the CAMP gene. This finding by Kulkarni and colleagues in 2015 comes from cultures of human bronchial epithelial cells. A study by Gottlieb and colleagues on serum samples from ten donors also saw that the level of induction differed between individuals, and that the difference was not fully explained by vitamin D levels. This relationship is what leads vitamin D and LL-37 to be discussed side by side so often.
What clinical trials have observed
Two clinical trials used topical LL-37 cream on chronic venous leg ulcers. The 2014 trial in 34 participants compared concentrations of 0.5, 1.6, and 3.2 mg/mL over four weeks. The 0.5 and 1.6 mg/mL groups showed healing rate constants around six times and three times that of the comparison group, and the cream was well tolerated in that study.
The highest level is not automatically the best
Interestingly, the highest concentration of 3.2 mg/mL did not give a greater result. The phase IIb HEAL LL-37 trial in 2021 then involved 148 patients with 0.5 or 1.6 mg/mL cream together with compression therapy, and its follow-up analysis saw a positive signal in wounds measuring at least 10 square cm. The authors recommended further studies designed specifically for that group of wounds. The concentration figures here are part of the study design, not a recommendation for use.
Reading LL-37 product information
For a guide to reading product information, read A guide to reading peptide product information. Also check the vial size listed on the product page.
Full details on LL-37 are in the Peptivia catalog. If there is anything you would like to ask before ordering, the Peptivia team is ready to help through Peptivia's official WhatsApp.
